Just wanted to bring your attention to this new article:
RAB32 S71R is a new pathogenic variant in PD, with a common founder haplotype in different populations. The new finding has been made in collaboration with the GP2 consortium.
Interestingly RAB32 interacts with LRRK2 (alphafold modelling and endogenously) and the pathogenic variant affects LRRK2 kinase activity and RAB10 phosphorylation. It is also involved in PINK1/mitochondrial function.
What are your thoughts on this?
Anyone who might be interested in a follow-up project?
Thanks for sharing, Joanne. Very cool research, I’ll be following!
@mattk I remember you mentioned LRRK2 is a research focus of yours, and @pmastrob I remember mitochondrial function is an interest of yours. Curious what you two think about these new findings?
Thank you @joanne.trinh for posting and @lmackenzie for tagging me. I’ve added this to my reading list! The paper looks interesting. Will post once I’ve given these findings some thought. I’m definitely interested in looking at polygenic contributors/modifiers of LRRK2.
Thanks Matt - let me know if you want to touch base on modifiers. RAB32 hasn’t yet been nominated as a modifier of LRRK2 in population-based studies, though this is an intriguing angle.